Alvotech And Stada Make Biosimilars Pact
Stada Gains Rights To Seven Biosimilars In Europe And Beyond
Alvotech and Stada have struck a deal that will give Stada exclusive rights to sell seven Alvotech biosimilars “in all key European markets” as well as certain other territories.
You may also be interested in...
Alvotech and Stada are on the verge of gaining the world’s second ever approval for a higher-strength Humira biosimilar, after the EMA’s CHMP endorsed the firms’ adalimumab under the names Hukyndra and Libmyris at its September meeting.
Stada has launched its Oyavas version of bevacizumab upon EU approval, initially rolling out the oncology biosimilar in Germany and the Netherlands with other countries to follow.
Cipla has expanded its partnership with Alvotech to cover the commercialization of four biosimilars in Australia and New Zealand, building on an existing alliance covering South Africa and emerging markets.